SCHEMBL1369842

SCHEMBL1369842

Cn1c(=O)n(-c2ncccc2CN(c2cncnc2)c2cccc(C#N)c2)c2ccccc21

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GRM5 P41594 4/20 0.37
PRKDC P78527 1/20 0.35
GRM4 Q14833 3/20 0.34
KCNN4 O15554 2/20 0.34
KCNA5 P22460 2/20 0.34
BCL6 P41182 1/20 0.34
CYP1A2 P05177 5/20 0.33
HSD17B10 Q99714 3/20 0.33
CASP1 P29466 2/20 0.33
CASP7 P55210 2/20 0.33
CYP3A4 P08684 4/20 0.33
CYP2C19 P33261 3/20 0.33
CYP2D6 P10635 3/20 0.32
ALDH1A1 P00352 2/20 0.32
NOS3 P29474 1/20 0.32
NOS1 P29475 1/20 0.32
NOS2 P35228 1/20 0.32
GRIN1 Q05586 1/20 0.32
GRIN2B Q13224 1/20 0.32
MEN1 O00255 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1369076 0.94 GRM5 (0.36) GRM5PRKDCGRM4KCNN4KCNA5
SCHEMBL1367495 0.82 PRKDC (0.35) PRKDCKCNN4KCNA5ALDH1A1NOS3
SCHEMBL1369322 0.75 MKNK1 (0.42) GRM5KCNN4KCNA5CYP1A2HSD17B10
SCHEMBL1366823 0.73 GRM5 (0.33) GRM5KCNN4KCNA5CYP1A2HSD17B10
SCHEMBL1368342 0.68 GRM5 (0.33) GRM5KCNN4KCNA5CYP3A4NOS3
SCHEMBL1367775 0.67 AR (0.36) KCNN4KCNA5NOS3NOS1NOS2
SCHEMBL1367811 0.67 GRM5 (0.32) GRM5KCNN4KCNA5CYP1A2HSD17B10
SCHEMBL1368340 0.66 CYP11B1 (0.34) GRM5KCNN4KCNA5CYP3A4NOS3
SCHEMBL1368624 0.66 CYP17A1 (0.43) ALDH1A1SMN1; SMN2
SCHEMBL1369936 0.66 MKNK1 (0.43) ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100004229-A1 Potassium Channel Inhibitors MERCK SHARP & DOHME CORP. 2010-01-07 US claimed
US-8067607-B2 Potassium channel inhibitors MERCK SHARP & DOHME CORP. (US) 2011-11-29 US disclosed
US-8067607-B2 Potassium channel inhibitors MERCK SHARP & DOHME CORP. (US) 2011-11-29 US disclosed
US-20100004229-A1 Potassium Channel Inhibitors MERCK SHARP & DOHME CORP. 2010-01-07 US disclosed
US-20100004229-A1 Potassium Channel Inhibitors MERCK SHARP & DOHME CORP. 2010-01-07 US disclosed
WO-2007089735-A2 POTASSIUM CHANNEL INHIBITORS MERCK & CO., INC. (US) 2007-08-09 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100004229-A1 Potassium Channel Inhibitors KCNJ2, KCNH2, KCNH3 GRM5 1811/4885PRKDC 3452/4885GRM4 3400/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.